| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2023 | -28.67% | BTIG | $0.35 → $5 | Maintains | Sell |
| 03/18/2022 | -85.73% | BTIG | → $1 | Downgrades | Neutral → Sell |
| 03/16/2022 | -78.6% | B of A Securities | $3 → $1.5 | Maintains | Underperform |
| 01/07/2022 | -57.2% | B of A Securities | → $3 | Downgrades | Neutral → Underperform |
| 09/27/2021 | -0.14% | JP Morgan | $10 → $7 | Downgrades | Neutral → Underweight |
| 08/12/2021 | 28.39% | Piper Sandler | → $9 | Downgrades | Overweight → Neutral |
| 08/11/2021 | 42.65% | JP Morgan | $17 → $10 | Downgrades | Overweight → Neutral |
| 03/09/2021 | 156.77% | BTIG | → $18 | Initiates Coverage On | → Buy |
| 03/09/2021 | 156.77% | JP Morgan | → $18 | Initiates Coverage On | → Overweight |
| 03/09/2021 | 99.71% | B of A Securities | → $14 | Initiates Coverage On | → Neutral |
| 03/09/2021 | 142.51% | Piper Sandler | → $17 | Initiates Coverage On | → Overweight |
What is the target price for Talis Biomedical (TLIS)?
The latest price target for Talis Biomedical (NASDAQ: TLIS) was reported by BTIG on August 16, 2023. The analyst firm set a price target for $5.00 expecting TLIS to fall to within 12 months (a possible -28.67% downside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Talis Biomedical (TLIS)?
The latest analyst rating for Talis Biomedical (NASDAQ: TLIS) was provided by BTIG, and Talis Biomedical maintained their sell rating.
When is the next analyst rating going to be posted or updated for Talis Biomedical (TLIS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Talis Biomedical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Talis Biomedical was filed on August 16, 2023 so you should expect the next rating to be made available sometime around August 16, 2024.
Is the Analyst Rating Talis Biomedical (TLIS) correct?
While ratings are subjective and will change, the latest Talis Biomedical (TLIS) rating was a maintained with a price target of $0.35 to $5.00. The current price Talis Biomedical (TLIS) is trading at is $7.01, which is out of the analyst's predicted range.
